Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

NCT07244380 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

T Lymphoblastic Leukemia/Lymphoma

Interventions

BIOLOGICAL: Autologous CD7-targeting CAR T cells

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.